These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28196209)

  • 1. An Important Step Forward for Biosimilars in Cancer Treatment.
    Schleicher SM; Seidman AD
    JAMA Oncol; 2017 Jul; 3(7):989-990. PubMed ID: 28196209
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab biosimilar shows potential for breast cancer.
    Baker H
    Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biosimilars in oncology. Focus on SB3 studies.].
    Del Re M; Del Mastro L
    Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.
    Cargnin S; Shin JI; Genazzani AA; Nottegar A; Terrazzino S
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):577-588. PubMed ID: 33005979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
    Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
    Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
    Waller CF; Möbius J; Fuentes-Alburo A
    Br J Cancer; 2021 Apr; 124(8):1346-1352. PubMed ID: 33589773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
    Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
    Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SB3 (Ontruzant
    Lamb YN
    BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
    Tian T; Ye J; Zhou S
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of Efficacy and Adverse Effects of Trastuzumab Biosimilar in Gastric Cancer].
    Okuda Y; Mikame Y; Shinada M; Yamaguchi H; Fujii H; Sudoh T
    Gan To Kagaku Ryoho; 2020 Sep; 47(9):1341-1344. PubMed ID: 33130696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
    Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
    Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
    Goyal P; Iyer J; Adhikary L; Vats B; Kabadi P; Pai H; Ranayhossaini D; Gouda S; Subbarao M; Mehta G; Saha A; Bera A; Sahu A; Kaur M; Singh A; Marwah A; Reddy Moole PK; Smith J; Melarkode R; Ullanat R
    Future Med Chem; 2021 Sep; 13(18):1531-1557. PubMed ID: 34289749
    [No Abstract]   [Full Text] [Related]  

  • 19. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
    Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
    Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.